LianBio【LIANY】

時価総額

$1783万

PER

アジア向けに医薬品を導入・開発する臨床段階のバイオ医薬品企業の新興企業。心血管・腫瘍・眼科・炎症で8候補と3件のレジスト試験を展開。21年11月の米国上場と23年2月のオミランコルのライセンス契約締結。中国・アジア太平洋・米国で展開。

	2021年 12月31日	2022年 12月31日
Cash and cash equivalents	228	79
Marketable securities	155	223
Prepaid expenses and other current assets	10	9
Other receivable	6	2
Total current assets	400	313
Restricted Cash, Noncurrent	20	0
Property and equipment, net	2	3
Operating lease right-of-use assets	5	4
Other non-current assets	0	0
Total assets	426	320
Accounts payable	3	1
Accrued expenses	10	20
Operating Lease, Liability, Current	1	2
Other current liabilities	1	0
Total current liabilities	15	24
Operating lease liabilities	4	2
Other liabilities	0	0
Nonrefundable research deposit	20	-
Total liabilities	39	26
Common Stock, Value, Issued	0	0
Additional paid-in capital	713	732
Accumulated other comprehensive (loss) income	1	-2
Accumulated deficit	-360	-470
Total LianBio shareholders’ equity	387	294
Non-controlling interest	34	34
Total shareholders’ equity	387	294
Total liabilities and shareholders’ equity	426	320